China-based Wuzhou Zhongheng Group (SHA: 6002532) has paid $52 million for a 10% stake in Oramed Pharma (Nasdaq: ORMP) and China rights to its two diabetes treatments, reports China Bio Today.
Oramed, based in Israel, develops oral versions of injected protein drugs. Details of the deal were not disclosed. In December 2014, Zhongheng invested $5 million in Oramed for a 7% stake in the company, which suggests the China rights to the diabetes treatments are worth over $40 million.
Recently, Oramed announced plans to begin a US Phase IIb trial of its oral insulin capsule product ORMD-0801.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze